Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.
Journal: Pediatric blood & cancer
Published: February 24, 2026
Maternal-Fetal Transmission of Diffuse Large B-Cell Lymphoma.
Journal: Pediatric blood & cancer
Published: September 10, 2025
Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.
Journal: The Lancet. Haematology
Published: July 03, 2025
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
Journal: British journal of haematology
Published: June 04, 2024
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Journal: Transplantation and cellular therapy
Published: November 08, 2022
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Journal: Leukemia
Published: April 30, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Journal: Blood advances
Published: October 18, 2021
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Journal: Pediatric blood & cancer
Published: March 19, 2021
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
Journal: British journal of haematology
Published: November 25, 2020
Last Updated: 09/26/2026